AustriaTuberculosis profile
Population  2015 8.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.078 (0.077–0.079) 0.91 (0.9–0.92)
Mortality (HIV+TB only) <0.01 (0–0.01) 0.02 (0–0.12)
Incidence  (includes HIV+TB) 0.65 (0.56–0.75) 7.6 (6.5–8.8)
Incidence (HIV+TB only) 0.016 (0.012–0.02) 0.19 (0.14–0.23)
Incidence (MDR/RR-TB)** 0.02 (<0.01–0.032) 0.23 (0.09–0.37)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.03 (0.023–0.037) 0.2 (0.13–0.27) 0.23 (0.16–0.31)
Males 0.011 (<0.01–0.014) 0.41 (0.32–0.49) 0.42 (0.33–0.51)
Total 0.041 (0.03–0.052) 0.61 (0.56–0.66) 0.65 (0.56–0.75)
TB case notifications, 2015  
Total cases notified 583
Total new and relapse 564
          - % tested with rapid diagnostics at time of diagnosis 53%
          - % with known HIV status  
          - % pulmonary 78%
          - % bacteriologically confirmed among pulmonary 87%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.1–0.15)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  14
(5–24)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.84–4.9) 17% (2.1–48)  
% notified tested for rifampicin resistance 61% 42% 436
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 13, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 13, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 74% 553
Previously treated cases, excluding relapse, registered in 2014 67% 12
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 77% 13
XDR-TB cases started on second-line treatment in 2013 67% 3
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data